NEW YORK (GenomeWeb) – Non-profit fundraising organization Stand Up to Cancer (SU2C) announced today the launch of four research projects that will use genetic and other technologies to detect and treat cancer at its earliest stages.
The projects are part of the SU2C Cancer Interception initiative and will specifically focus on lung and pancreatic cancer. They will be be funded with a total of $16.6 million provided by SU2C, the Lustgarten Foundation for Pancreatic Cancer Research, LUNGevity, and the American Lung Association.
In the first project, a team led by University of Texas MD Anderson Cancer Center scientists will receive $7 million to perform genetic screening on family members of 2,000 pancreatic cancer patients to identify carriers of disease-risk mutations. Positive mutation carriers will then undergo imaging testing, and those found to have precancerous lesions will be treated with a vaccine designed to trigger an immune response against the cancer. The researchers — who include collaborators from Johns Hopkins University and the University of California, San Diego — also aim to develop a blood test for pancreatic cancer for use in high-risk individuals.
The second project is being led by scientists at the Massachusetts General Hospital and NYU Langone, who